Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Isocell Nutra is a French biotechnology company specializing in the development of bioactive nutritional supplements and dermo-cosmetic products. The company is best known for creating GliSODin, the first orally effective form of Superoxide Dismutase (SOD), achieved by combining the enzyme with a wheat protein (gliadin) to protect it from gastric degradation. Isocell Nutra focuses on oxidative stress management, offering solutions for skin health, anti-aging, and immune support. Their research-driven approach has led to numerous clinical studies validating the efficacy of their SOD-based formulations in various therapeutic and aesthetic applications. The company operates globally, providing patented ingredients and finished products to the healthcare and aesthetic medicine markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Isocell Nutra.